IgE receptor antagonists - Pipeline Insight, 2022
![](/report_cover/8047/ige-receptor-antagonists-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “IgE receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in IgE receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
IgE receptor antagonists: Overview
Immunoglobulin E is responsible for the pathogenesis of many allergic diseases including asthma. The primary role of IgE is defense against parasitic disease such as helminthes and protozoa. IgE, like all immunoglobulins, is composed of two light chains and two identical heavy chains. The heavy chain for IgE is epsilon. IgE is a monomer and consists of four constant regions. The constant region, C-epsilon-3, binds to both the low- and high-affinity IgE receptor. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness.
Report Highlights
This segment of the IgE receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IgE receptor antagonists Emerging Drugs
Further product details are provided in the report……..
IgE receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different IgE receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
IgE receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses IgE receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgE receptor antagonists drugs.
IgE receptor antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “IgE receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in IgE receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
IgE receptor antagonists: Overview
Immunoglobulin E is responsible for the pathogenesis of many allergic diseases including asthma. The primary role of IgE is defense against parasitic disease such as helminthes and protozoa. IgE, like all immunoglobulins, is composed of two light chains and two identical heavy chains. The heavy chain for IgE is epsilon. IgE is a monomer and consists of four constant regions. The constant region, C-epsilon-3, binds to both the low- and high-affinity IgE receptor. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence IgE receptor antagonists R&D. The therapies under development are focused on novel approaches for IgE receptor antagonists.
This segment of the IgE receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IgE receptor antagonists Emerging Drugs
- Genolair (Omalizumab biosimilar): Generium Pharmaceuticals
- Omalizumab (Xolair): Zhimeng Biopharma
Further product details are provided in the report……..
IgE receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different IgE receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on IgE receptor antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
IgE receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses IgE receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgE receptor antagonists drugs.
IgE receptor antagonists Report Insights
- IgE receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing IgE receptor antagonists drugs?
- How many IgE receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IgE receptor antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IgE receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for IgE receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Generium Pharmaceuticals
- Genentech
- Celltrion
- Glenmark Pharmaceuticals Ltd
- Helixmith
- United BioPharma
- Biosana
- PharmAbcine
- Hisun BioRay
- Aimmune Therapeutics
- Synermore Biologics
- Shanghai Biomabs Pharmaceuticals
- Eden Biologics
- Genolair
- Omalizumab
- CT-P 39
- GBR 310
- PG 102
- BP-001
- UB 221
- PMC 904
- HS-632
- AIMab 7195
- SYN-008
- CMAB-007
Introduction
Executive Summary
IgE receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
IgE receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Genolair: Generium Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
PG 102: Helixmith
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
UB 221: United BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
HS-632: Hisun BioRay
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
IgE receptor antagonists Key Companies
IgE receptor antagonists Key Products
IgE receptor antagonists- Unmet Needs
IgE receptor antagonists- Market Drivers and Barriers
IgE receptor antagonists- Future Perspectives and Conclusion
IgE receptor antagonists Analyst Views
IgE receptor antagonists Key Companies
Appendix
Executive Summary
IgE receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
IgE receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Genolair: Generium Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
PG 102: Helixmith
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
UB 221: United BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
HS-632: Hisun BioRay
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
IgE receptor antagonists Key Companies
IgE receptor antagonists Key Products
IgE receptor antagonists- Unmet Needs
IgE receptor antagonists- Market Drivers and Barriers
IgE receptor antagonists- Future Perspectives and Conclusion
IgE receptor antagonists Analyst Views
IgE receptor antagonists Key Companies
Appendix